Akeso (HKSE:09926) FCF Yield % : 4.12 (As of May. 19, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Akeso FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Akeso's Trailing 12-Month Free Cash Flow is HK$1,737 Mil, and Market Cap is HK$42,167 Mil. Therefore, Akeso's FCF Yield % for today is 4.12%.

The historical rank and industry rank for Akeso's FCF Yield % or its related term are showing as below:

HKSE:09926' s FCF Yield % Range Over the Past 10 Years
Min: -21.16 Med: -2.75 Max: 5.2
Current: 4.12

During the past 6 years, the highest FCF Yield % of Akeso was 5.20%. The lowest was -21.16%. And the median was -2.75%.

HKSE:09926's FCF Yield % is ranked better than
94.28% of 1557 companies
in the Biotechnology industry
Industry Median: -14.14 vs HKSE:09926: 4.12

Akeso's FCF Margin % for the quarter that ended in Dec. 2023 was -106.39%.

Akeso FCF Yield % Historical Data

The historical data trend for Akeso's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso FCF Yield % Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-4.22

-7.57

-6.31

4.45

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial						-9.44	-10.97	-7.17	18.34	-5.07

Competitive Comparison of Akeso's FCF Yield %

For the Biotechnology subindustry, Akeso's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Akeso's FCF Yield % falls into.

Akeso FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Akeso's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	1737.23	/	39025.0448
	=	4.45%

Akeso's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-988.425	*	2	/	39025.0448
	=	-5.07%

Akeso FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Akeso FCF Yield % Related Terms

Thank you for viewing the detailed overview of Akeso's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines